论文部分内容阅读
目的 探讨重症肌无力（ＭＧ）患者血清ＩｇＧ－乙酰胆硷受体抗体（ＡＣｈＲＡｂ）亚型的分布规律及其临床意义。方法 采用ＡＢＣ－ＥＬＩＳＡ法检测４３例ＭＧ组和２５例临床对照组、２０例正常对照组血清中ＩｇＧ－ＡＣｈＲＡｂ亚型ＩｇＧ１－４。结果 ＭＧ组与两对照组相比ＩｇＧ１和ＩｇＧ４亚型抗体无显著差别，ＩｇＧ２亚型抗体显著升高（Ｐ＜０．０５），ＩｇＧ３亚型抗体显著降低（Ｐ＜０．０５）；ＭＧ组各临床类型间各亚型抗体无显著差别。结论ＩｇＣ－ＡＣｈＲＡｂ亚型以ＩｇＧ２活性为主，但未显示与ＭＧ临床类型有关。
Objective To investigate the distribution and clinical significance of serum IgG-acetylcholine receptor antibody (AChRAb) subtype in patients with myasthenia gravis (MG). Methods ABC-ELISA method was used to detect IgG-AChRAb subtype IgG1-4 in serum of 43 patients with MG and 25 patients with clinical control and 20 patients with normal control. Results Compared with the two control groups, there was no significant difference in the IgG1 and IgG4 subtype antibodies between the MG group and the IgG2 subtype group (P <0.05) and the IgG3 subtype group (P <0.05) There was no significant difference in each subtype antibody between clinical types. Conclusion IgC-AChRAb subtype is mainly IgG2 activity, but it is not related to the clinical type of MG.